Skip to main content

Table 2 Risk of bias assessment of included studies

From: Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

Studies Representativeness of exposed cohort Selection of non-exposed cohort Ascertainment of exposure Demonstration Comparability Assessment of outcome Follow-up long enougha Adequacy of follow-upb Total score
Case Reports
 Franz 2006 Somewhat representative* No non-exposed cohort Secure record* Yes* No Record linkage* Variable Complete* 5
 Wienecke 2006 Somewhat representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* Complete* 6
 Birca 2010 Somewhat representative* No non-exposed cohort Secure record* Yes* No Record linkage* Unclear Complete* 5
 Lam 2010 Somewhat representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* Complete* 6
Cohort Prospective
 Krueger 2010 Truly representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* Complete* 6
 Dabora 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* 8 out of 36 lost follow-up (22 %)* 6
 Davies 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* 4 out of 16 lost follow-up (25 %)* 6
 Lopez 2011 Truly representative* No non-exposed cohort Secure record* Yes* No Record linkage* Yes* 1 out of 17 lost follow-up (5 %)* 6
  1. aLength of follow-up of at least 6 months is considered sufficient
  2. bLost of follow-up <30 % is considered acceptable; *Indicates point that contribute to Total Score